Novo (NYSE:NVO) has faced significant challenges over the past couple of years. The company's shares have dropped by more than 60% as a result. However, the drugmaker is looking for ways to recover. Management set several goals for 2030 that could enable Novo to improve its financial results. Let's look into whether Novo can achieve these goals and deliver competitive returns over the next few years. Image source: The Motley Fool. Novo's recent challenges stem from the fact that it generates most of its money from its GLP-1 products, including Wegovy, Ozempic, and Rybelsus. However, it has lost market share in this area to Eli Lilly (NYSE:LLY).
CryptoAlerta — análise de criptomoedas e mercado em tempo real